Notice for Sipavibart (AstraZeneca Pty Ltd)
Active ingredients
Sipavibart
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
AZD3152 is indicated for the pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who are immunocompromised due to a medical condition or receipt of immunosuppressive medications or treatments.
Therapeutic area
Infectious diseases